Connect Biopharma Holdings (CNTB) Change in Receivables (2024 - 2026)

Connect Biopharma Holdings has disclosed Change in Receivables across 3 years of filings, most recently posting $2.9 million for Q2 2026.

• In Q2 2026, Change in Receivables rose 36800.0% year-over-year to $2.9 million; the TTM figure through Jun 2026 stood at $2.9 million (changed N/A YoY), while the FY2025 annual figure was -$776000.0, down 198.35% from the prior year.
• Change in Receivables came in at $2.9 million for Q2 2026 at Connect Biopharma Holdings, up from -$13000.0 in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $5.0 million in Q3 2024 to a low of -$4.2 million in Q4 2024.
• Average Change in Receivables over 3 years is $367000.0, with a median of -$6000.0 recorded in 2025.
• Year-over-year, Change in Receivables sank 99.66% in 2025 and surged 36800.0% in 2026.
• Over 3 years, Change in Receivables stood at -$4.2 million in 2024, then soared by 99.91% to -$4000.0 in 2025, then surged by 73500.0% to $2.9 million in 2026.
• Per Business Quant data, the three most recent Change in Receivables figures were $2.9 million in Q2 2026, -$13000.0 in Q1 2026, and -$4000.0 in Q4 2025.